Develops targeted cancer therapies using synthetic lethality to selectively kill cancer cells while sparing healthy tissues.
Tango Therapeutics, Inc. is a pioneering biotechnology company dedicated to the discovery and advancement of novel cancer therapies. Focused on leveraging synthetic lethal interactions, Tango Therapeutics develops innovative drugs aimed at effectively treating various forms of cancer. At the forefront of its pipeline is TNG908, a synthetic lethal small molecule inhibitor targeting protein arginine methyltransferase 5 (PRMT5). This promising candidate is specifically tailored for cancers characterized by methylthioadenosine phosphorylase deletions, showcasing Tango's commitment to precision medicine in oncology.
In addition to TNG908, Tango Therapeutics is actively developing Ubiquitin-specific protease 1 inhibitors designed to address BRCA1 or BRCA2-mutant cancers. These inhibitors hold significant potential in targeting specific genetic vulnerabilities associated with these types of cancer. Furthermore, the company is advancing Target 3 therapies for STK11-mutant cancers, further expanding its portfolio of precision oncology treatments.
Founded in 2017 and headquartered in Cambridge, Massachusetts, Tango Therapeutics has established strategic collaborations to enhance its research and development efforts. Notably, the company has partnered with Gilead Sciences, Inc. to jointly discover, develop, and commercialize a robust pipeline of cancer therapies. This collaboration underscores Tango's commitment to accelerating the delivery of innovative treatments to cancer patients worldwide.
Driven by a strong scientific foundation and a dedicated team of researchers, Tango Therapeutics continues to push the boundaries of cancer therapy. With a focus on identifying and exploiting genetic vulnerabilities unique to cancer cells, the company aims to redefine treatment paradigms and improve outcomes for patients facing challenging malignancies.